The 340B program has a name that sounds like a line on a tax form, and most patients have never heard of it. Under the program, drug manufacturers sell outpatient medicines at a steep discount to hospitals and clinics that qualify, mostly because they serve a large share of patients on Medicaid or without insurance. In most cases the hospital is then paid the usual rate by whoever covers the patient, and it keeps the difference. Congress created the program in 1992 to help those facilities stretch scarce resources further for the patients who need it most. What the law never required was a way to show that it does.
That gap was the subject of the 340B panel at the 2026 State of the Patient Summit on Capitol Hill, now the latest episode of the State of the Patient podcast. Terry Wilcox asked three people who see the program from very different places a single question: how much of the money actually reaches the patient, and how would anyone know?
Dr. Anthony DiGiorgio, a neurosurgeon at UC San Francisco who operates at San Francisco General, was clear that he speaks for himself and not for his hospital. He described what he called one of the ironies of 340B: the program does less for true safety-net hospitals than for large health systems with wealthier patients. By his account, San Francisco General runs on roughly a $1.4 billion budget and earns about $20 million a year from 340B, because most of its patients are on Medicaid. The spread a hospital earns comes from patients with good commercial insurance, so a hospital serving more of them can earn far more.
Ryan Long of the Paragon Health Institute went further, arguing that the program's structure sends more money to wealthier hospitals and adds to federal spending and premiums. That second point is contested: the discounts themselves are paid by manufacturers, not taxpayers, and defenders of the program make that case often.
Thomas Johnson, who leads the Alliance to Save America's 340B Program, walked through the four comprehensive proposals now in front of Congress: the ACCESS Act and the SECURE Act in the House, Senator Bill Cassidy's 340B for Patients Act discussion draft, and the bipartisan SUSTAIN Act in the Senate. They overlap on transparency and on the satellite clinics hospitals call child sites, and they part ways on contract pharmacies and rebates. The panel also weighed whether patients' out-of-pocket costs for 340B drugs should be capped on a sliding scale, as the Cassidy draft would do.
Terry raised Patients Rising's review of more than 900 medical bankruptcy filings that listed a 340B hospital as a creditor, including people sent to collections for bills they could never pay. She was equally clear that the filings can't show any of those bills involved a 340B drug. The question they raise is simpler: why weren't these patients screened for help before it came to that?
The panel didn't agree on everything, and it wasn't meant to. But nobody argued that hospitals caring for underserved patients should get less help. The disagreement was about whether a program built on the spread between a discounted price and a full one can ever get that help to the right place. Dr. DiGiorgio proposed taking out the middleman entirely and putting the subsidy as close to the patient as possible. Johnson urged patients to find out whether their own hospital is a 340B hospital.
That's the practical takeaway for anyone with a hospital bill that doesn't make sense: ask whether the hospital is in the 340B program, and ask about its charity care program.
Listen to the full episode and read the transcript: [EPISODE PAGE LINK]